MANAGEMENT DISCUSSION AND ANALYSIS:
a. Industry Structure and Developments
- Indian Pharma Position: 3rd largest globally by volume, 13th by value.
- Market Size FY 2023-24:
o Total: USD 50 billion o Domestic: USD 23.5 billion o Exports: USD 26.5 billion
- Growth: Expected CAGR of 11.34% (IBEF projection).
b. SWOT Analysis
Strengths
1. Experienced Management: Strong, multi-disciplinary leadership with a deep understanding of pharma operations including R&D, regulatory affairs, and global marketing.
2. Modern Manufacturing Facilities: WHO-cGMP compliant plant in Gujarat with flexibility across multiple formulations and therapeutic areas.
3. Advanced Technology: Use of TOFFLON Lyophiliser improves product stability and allows entry into regulated international markets.
4. Diverse Therapeutic Range: 22 therapeutic categories covered, including high-demand segments like anti-infectives, PPIs, and antifungals.
5. Long-Term Client Relationships: Top 5 clients contribute 45.40% of sales; relationships over 5 years.
6. International Accreditation: Approved by regulatory bodies in 14 countries; 321 product registrations worldwide.
Weakness
- Competitive Pressure from Local Players: Smaller players may disrupt pricing or customer relationships via notional benefits.
Opportunities
1. Main Board Listing: Migration to NSEs main board in 2019 enhanced visibility and investor confidence.
2. DSIR-Recognized R&D: Government-recognized R&D center supports innovation and technical credibility.
3. Oncology Expansion: Subsidiary "Sakar Oncology Pvt. Ltd." established with a USFDA-standard facility- positions company in high-growth, high-barrier segment.
Threats
- Regulatory Risk: Constant regulatory changes can impact operations and pricing.
- Product Lifecycle Decline: Natural decline in older products may stagnate growth; mitigated via product basket flexibility and multi-brand strategy.
c. Segment-Wise Performance
Company operates under a single business segment, hence no segmented reporting is required.
d. Recent T rends & Future Outlook
- Global Recognition: Indian pharmas emergence as a credible, quality-driven supplier benefits the company.
- Lyophilized Products: Increased focus on high-tech, high-stability products as a growth strategy.
- Future Strategy: Broaden product portfolio, enter new markets, and prioritize higher-margin and differentiated products.
e. Risks and Concerns
- Key Risk Areas: Pricing pressure, country-specific risks, regulatory shifts, and product investment decisions.
- Risk Mitigation: Diversified product mix, adherence to compliance standards, and balanced exposure across countries.
f. Internal Control Systems
- Robust Controls: Adequate for company size and scope, ensuring accuracy in accounting, fraud prevention, asset protection, and timely reporting.
g. Financial Performance
- To be detailed separately in the Directors Report for FY 2024-25.
h. Human Resources & Industrial Relations
- Employee Development: Ongoing initiatives to boost morale and skillsets.
- Sales Force Empowerment: Investment in knowledge systems and R&D-backed training for better customer engagement.
- Industrial Relations: Remained cordial and stable throughout the year.
Key Takeaway:
The company is strategically well-positioned in the growing Indian and global pharmaceutical landscape with strong infrastructure, international credentials, and a future-focused plan that includes entry into high- growth areas like oncology.
i. Key Financial Ratios:
Key Ratios |
FY 2024-25 | FY 2023-24 | Change % | Explanation, if required |
Debtors Turnover |
63 Days | 60 Days | 5% | The receivable days are in line with the previous year. |
Inventory Turnover |
166 Days | 76 Days | 118.42% | The inventory holding period has increased on account of increased levels of inventory held to meet the increased demands. |
Interest Coverage Ratio |
6.47 | 3.09 | 109.39% | Interest coverage ratio has significantly improved on account of improvement in the operating profits available to service debt. |
Current Ratio |
1.41 | 1.21 | 16.53% | The current ratio has improved compared to the previous year. |
Debt Equity Ratio |
0.23 | 0.30 | -23.33% | The debt-equity ratio has improved on account of increase in Shareholders fund and repayment of term loans. |
Operating Profit Margin (%) |
29 | 21.49 | 34.95% | The operating profit margin has increased compared to previous year on account of increase in revenue from operations and optimisation of cost of sales. |
Net Profit Margin (%) |
10% | 7.61% | 31.41% | The Net profit margin has improved compared to previous year on account of increase in revenue from operations and optimisation of costs. |
Return on Net worth |
6.13 | 4.45% | 37.75% | The return on net-worth has improved compared to previous on account of improvement in the profits after tax of the business. |
j. Cautionary Statement:
Statement in this Management Discussion and Analysis Report, describing the Companys objectives, estimates and expectations may constitute ‘Forward Looking Statements within the meaning of applicable laws or regulations. Actual results might differ materially from those either expressed or implied.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.